Monthly Archives: September 2018

//September

Public Listings for Caprelsa

Caprelsa (vandetanib) is indicated for the treatment of symptomatic or progressive Medullary thyroid cancer in adult patients with unresectable locally advanced or metastatic disease. Alberta Health Services has put the [...]

By | 2018-09-18T23:32:14+00:00 September 18th, 2018|Treatment News|Comments Off on Public Listings for Caprelsa

Patient Input – Treatment with Telotristat

TELOTRISTAT is an adjunct to somatostatin analogue therapy for the long-term treatment of carcinoid syndrome to improve symptom control in adult patients with metastatic neuroendocrine tumours.The company who makes telotristat [...]

By | 2018-09-03T18:47:17+00:00 September 3rd, 2018|Survey, Treatment News|Comments Off on Patient Input – Treatment with Telotristat